drugset
drugset / Trial / NCT02420691

Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin

NCT02420691 ↗

Phase 2 Completed 21 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collabNovartis · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well ribociclib works in treating patients with neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach, and pancreas, that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced tumors). Ribociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2015-08-25
Primary completion
2019-06-05
Completion
2019-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribociclib Small molecule — Oral

Indications

duodenal neuroendocrine tumor, well differentiated, low or intermediate grade functional pancreatic neuroendocrine tumor gastric neuroendocrine neoplasm lung neuroendocrine neoplasm non-functional pancreatic neuroendocrine tumor thymus neoplasm